JAMA Network
About The Study: In this randomized double-blind clinical trial of healthy adults administered cannabidiol (CBD), 5 mg/kg/d for 28 days, 8 (5.6%) experienced liver enzyme level elevations and 7 (4.9%) met protocol defined criteria for potential drug-induced liver injury. Participants did not experience clinical symptoms related to liver function during this 28-day study and hepatic enzymes returned to normal within 1 to 2 weeks following discontinuation. The findings of this study underscore the need for further investigation on the long-term effects of CBD use, its impact on various populations, and the safety of lower doses commonly used by consumers.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
